Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19025220 | GELS FOR INSULIN DELIVERY | January 2025 | April 2025 | Allow | 3 | 1 | 0 | No | No |
| 19004850 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18975144 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | December 2024 | February 2025 | Allow | 2 | 1 | 0 | No | No |
| 18911732 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | October 2024 | December 2024 | Allow | 2 | 1 | 0 | No | No |
| 18897657 | OPHTHALMIC FORMULATIONS AND METHODS OF USE | September 2024 | January 2025 | Allow | 4 | 1 | 0 | No | No |
| 18791632 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | August 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18789870 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | July 2024 | September 2024 | Allow | 2 | 1 | 0 | No | No |
| 18755045 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | June 2024 | August 2024 | Allow | 2 | 1 | 0 | No | No |
| 18667581 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | May 2024 | April 2025 | Allow | 11 | 2 | 0 | No | No |
| 18664248 | CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAME | May 2024 | December 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18643422 | NERATINIB-CYCLODEXTRIN COMPOSITION AND METHOD FOR PREPARING SAME | April 2024 | February 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18633642 | PHARMACEUTICAL COMPOSITION FOR TREATING OR IMPROVING EDEMA AND BLOOD STASIS AFTER OPEN SURGERY | April 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18623901 | COMPOSITIONS AND FORMULATIONS FOR USE OF A PK INHIBITOR FOR THE PREVENTION, TREATMENT, AND IMPROVEMENT OF SKIN DISEASES, CONDITIONS, AND DISORDERS | April 2024 | December 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18588820 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | August 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18588996 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | September 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18588938 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | August 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18588687 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | July 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18588892 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | February 2024 | August 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18425208 | TUNABLE, CONTROLLED-RELEASE, URETHANE-CONTAINING ELASTOMERS AND PROCESSES OF FORMING THE SAME | January 2024 | February 2025 | Abandon | 13 | 0 | 1 | No | No |
| 18416293 | Encased Tamper Resistant Controlled Release Dosage Forms | January 2024 | June 2025 | Allow | 16 | 2 | 0 | No | No |
| 18411663 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | January 2024 | June 2024 | Allow | 5 | 1 | 0 | No | No |
| 18401652 | FRACTIONATED RADIOTHERAPY AND CHEMOTHERAPY WITH AN OXYGEN THERAPEUTIC | January 2024 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18397342 | POLYLACTIC ACID MICROSPHERE, POLYLACTIC-CO-GLYCOLIC ACID MICROSPHERE AND METHOD OF PREPARING THE SAME | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18395565 | COMPOSITIONS AND METHODS FOR MINIMIZING EFFECTS OF ALCOHOL INTOXICATION | December 2023 | August 2024 | Allow | 8 | 2 | 0 | No | No |
| 18539830 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT | December 2023 | June 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18529137 | PHARMACEUTICAL COMPOSITION OF DILTIAZEM HYDROCHLORIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | December 2023 | April 2024 | Allow | 4 | 0 | 1 | No | No |
| 18519955 | NEBULIZATION FORMULATIONS FOR DELIVERY TO LOWER RESPIRATORY TRACT | November 2023 | March 2025 | Allow | 16 | 1 | 1 | No | No |
| 18488366 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18472743 | METHODS FOR ORAL PAIN RELIEF | September 2023 | April 2024 | Allow | 6 | 0 | 0 | No | No |
| 18460763 | Compositions for Enhancing Bioavailability of Pharmaceuticals, Supplements and Ingested Substances | September 2023 | June 2025 | Abandon | 21 | 4 | 0 | No | No |
| 18241523 | TOPICAL SKIN CREAM | September 2023 | December 2023 | Allow | 4 | 1 | 0 | No | No |
| 18241540 | TOPICAL SKIN CREAM | September 2023 | November 2023 | Allow | 2 | 1 | 0 | No | No |
| 18456759 | BORTEZOMIB COMPOSITIONS | August 2023 | April 2024 | Allow | 8 | 1 | 0 | No | No |
| 18226572 | THERAPEUTIC COMPOSITION INCLUDING PHENOLIC COMPOUNDS DERIVED FROM OPUNTIA LITTORALIS | July 2023 | March 2024 | Allow | 8 | 2 | 1 | No | No |
| 18356901 | HYDROGEL PRODRUG FOR TREATMENT | July 2023 | August 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18355964 | SOLID PREPARATION, METHOD FOR PRODUCING SOLID PREPARATION, AND METHOD FOR GENERATING HYDROGEN | July 2023 | May 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18222331 | BLEACH COMPOSITIONS | July 2023 | May 2024 | Allow | 10 | 1 | 0 | No | No |
| 18212471 | ANTIMICROBIAL SUPERABSORBENT COMPOSITIONS | June 2023 | October 2024 | Allow | 16 | 1 | 0 | No | No |
| 18327658 | HYDROGEL PRODRUG FOR TREATMENT | June 2023 | May 2024 | Allow | 11 | 1 | 0 | No | No |
| 18200958 | ANTIBODY BIOPHARMACEUTICAL FORMULATIONS INCLUDING POLYMER EXCIPIENTS | May 2023 | February 2024 | Allow | 8 | 1 | 1 | No | No |
| 18197787 | TOPICAL SKIN CREAM | May 2023 | November 2023 | Allow | 6 | 2 | 1 | No | No |
| 18317786 | PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT | May 2023 | November 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18310549 | EXTENDED RELEASE PLASTIC FORMULATION | May 2023 | December 2023 | Allow | 8 | 1 | 0 | No | No |
| 18136012 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18131715 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | April 2023 | April 2024 | Allow | 13 | 1 | 0 | No | No |
| 18192955 | 5HT AGONISTS FOR TREATING DISORDERS | March 2023 | June 2025 | Allow | 27 | 1 | 1 | No | No |
| 18128705 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18125106 | THERAPEUTIC COMPOSITION INCLUDING PHENOLIC COMPOUNDS DERIVED FROM OPUNTIA LITTORALIS | March 2023 | September 2023 | Allow | 5 | 1 | 1 | No | No |
| 18188384 | BORTEZOMIB COMPOSITIONS | March 2023 | July 2023 | Allow | 4 | 1 | 0 | No | No |
| 18122416 | ZWITTERIONICALLY MODIFIED POLYMERS AND HYDROGELS | March 2023 | April 2025 | Allow | 25 | 0 | 1 | No | No |
| 18175020 | Compositions for Enhancing Bioavailability of Pharmaceuticals, Supplements and Ingested Substances | February 2023 | September 2024 | Allow | 18 | 2 | 1 | No | No |
| 18175442 | MUCOADHESIVE COMPOSITIONS FOR DIRECTIONAL DELIVERY OF ACTIVE AGENTS | February 2023 | August 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18169571 | TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN | February 2023 | September 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 18109421 | FULVESTRANT FORMULATIONS AND METHODS OF THEIR USE | February 2023 | November 2024 | Allow | 21 | 2 | 0 | No | No |
| 18166416 | LYOPROTECTANT COMPOSITIONS AND USES THEREOF | February 2023 | July 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 18007003 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL ADMINISTRATION OF A COBALAMIN COMPOUND | January 2023 | September 2023 | Allow | 8 | 1 | 0 | No | No |
| 18096686 | Encased Tamper Resistant Controlled Release Dosage Forms | January 2023 | October 2023 | Allow | 9 | 1 | 0 | No | No |
| 18153528 | Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile | January 2023 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18150292 | Compositions Containing Microcapsules | January 2023 | March 2025 | Allow | 26 | 3 | 0 | No | No |
| 18150152 | COMPOSITIONS AND METHODS FOR TREATING EOSINOPHILIC DISORDERS | January 2023 | December 2024 | Allow | 23 | 0 | 1 | No | No |
| 18146022 | BIOABSORBABLE POLYMERIC COMPOSITION FOR A MEDICAL DEVICE | December 2022 | July 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18145463 | PULLULAN CAPSULES | December 2022 | October 2023 | Allow | 9 | 1 | 0 | No | No |
| 17994166 | FRACTIONATED RADIOTHERAPY AND CHEMOTHERAPY WITH AN OXYGEN THERAPEUTIC | November 2022 | September 2023 | Allow | 10 | 1 | 0 | No | No |
| 17985220 | FORMULATIONS OF ENZALUTAMIDE | November 2022 | January 2025 | Allow | 27 | 3 | 0 | Yes | Yes |
| 17979822 | DEODORANT COMPOSITIONS | November 2022 | June 2023 | Allow | 8 | 1 | 0 | No | No |
| 17965483 | TOPICAL SKIN COMPOSITIONS FOR TREATING WRINKLES | October 2022 | October 2023 | Allow | 12 | 1 | 0 | No | No |
| 18046221 | PUTRESCINE TOPICAL FORMULATIONS | October 2022 | February 2024 | Abandon | 16 | 1 | 1 | No | No |
| 17959681 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | October 2022 | March 2023 | Allow | 6 | 1 | 0 | No | No |
| 17934901 | BORTEZOMIB COMPOSITIONS | September 2022 | December 2022 | Allow | 3 | 1 | 0 | No | No |
| 17890796 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | August 2022 | August 2023 | Allow | 12 | 1 | 1 | No | No |
| 17864909 | ST-246 (tecovirimat monohydrate) SUSPENSION FORMULATIONS | July 2022 | June 2023 | Allow | 11 | 1 | 0 | No | No |
| 17862491 | RIFAXIMIN COMPLEXES | July 2022 | September 2023 | Abandon | 15 | 2 | 0 | No | No |
| 17857985 | COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION | July 2022 | February 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 17789530 | EXTENDED RELEASE PLASTIC FORMULATION | June 2022 | February 2023 | Allow | 7 | 0 | 0 | No | No |
| 17808342 | DISSOLVABLE POLYMERIC EYE INSERTS WITH A BIODEGRADABLE POLYMER AND METHOD OF USING THE SAME | June 2022 | May 2023 | Allow | 11 | 1 | 0 | No | No |
| 17845074 | Additive Compositions for Pigmented Disinfection and Methods Thereof | June 2022 | November 2022 | Allow | 5 | 1 | 0 | No | No |
| 17839089 | PHYTOTHERAPEUTIC PRODUCT FOR CORRECTION OF SYMPTOM-COMPLEX OF FIBROCYSTIC CHANGES OF MAMMARY GLAND | June 2022 | September 2022 | Allow | 3 | 1 | 0 | No | No |
| 17836588 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | June 2022 | February 2023 | Allow | 8 | 2 | 0 | Yes | No |
| 17831946 | Hydrocortisone Acetate Suppository Formulation For Treatment Of Disease | June 2022 | July 2024 | Allow | 25 | 4 | 0 | Yes | No |
| 17745190 | COMPOSITIONS AND METHODS FOR PREVENTING AND REVERSING ASPECTS OF AGING | May 2022 | February 2024 | Allow | 21 | 2 | 0 | No | No |
| 17740790 | NEBULIZATION FORMULATIONS FOR DELIVERY TO LOWER RESPIRATORY TRACT | May 2022 | July 2023 | Allow | 14 | 1 | 0 | No | No |
| 17662462 | TUNABLE, CONTROLLED-RELEASE, URETHANE-CONTAINING ELASTOMERS AND PROCESSES OF FORMING THE SAME | May 2022 | September 2023 | Allow | 16 | 1 | 0 | No | No |
| 17726936 | METHOD AND SYSTEM FOR MAKING PERSONALIZED NUTRITIONAL AND PHARMACEUTICAL FORMULATIONS USING ADDITIVE MANUFACTURING | April 2022 | November 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17726944 | HYDROGEL PRODRUG FOR TREATMENT | April 2022 | April 2023 | Allow | 12 | 1 | 0 | No | No |
| 17725606 | Implantable Device for Sustained Release of a Macromolecular Drug Compound | April 2022 | June 2025 | Allow | 38 | 2 | 0 | No | No |
| 17659507 | BOTANICAL PAIN RELIEF OINTMENT | April 2022 | April 2024 | Allow | 24 | 2 | 0 | No | No |
| 17719078 | Ophthalmic Composition | April 2022 | October 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17711280 | MICELLE FOR SOLUBILIZING A SPARINGLY WATER-SOLUBLE INGREDIENT AND SOLUTION COMPRISING THE SAME | April 2022 | March 2025 | Allow | 35 | 1 | 1 | No | No |
| 17695230 | PACLITAXEL-ALBUMIN-BINDING AGENT COMPOSITIONS AND METHODS FOR USING AND MAKING THE SAME | March 2022 | April 2025 | Abandon | 37 | 3 | 0 | No | No |
| 17654021 | COMPOSITIONS AND USES OF LOCALLY-APPLIED ANTIMICROBIAL SYNTHETIC CATIONIC POLYPEPTIDE(S) WITH ENHANCED PERFORMANCE AND SAFETY | March 2022 | December 2024 | Allow | 33 | 2 | 0 | No | No |
| 17652552 | FIBROUS CONSTRUCTS WITH THERAPEUTIC MATERIAL PARTICLES | February 2022 | February 2025 | Allow | 36 | 4 | 1 | Yes | No |
| 17679973 | SOLID PREPARATION, METHOD FOR PRODUCING SOLID PREPARATION, AND METHOD FOR GENERATING HYDROGEN | February 2022 | April 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17672341 | POLYMER EXCIPIENTS FOR DRUG DELIVERY APPLICATIONS | February 2022 | October 2023 | Allow | 20 | 1 | 0 | No | No |
| 17650664 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | February 2022 | July 2023 | Allow | 17 | 2 | 0 | Yes | No |
| 17667010 | NON-AQUEOUS PATCH | February 2022 | June 2023 | Allow | 16 | 1 | 0 | No | No |
| 17591806 | COMPOSITIONS AND DEVICES INCORPORATING WATER-INSOLUBLE THERAPEUTIC AGENTS AND METHODS OF THE USE THEREOF | February 2022 | March 2023 | Allow | 13 | 1 | 0 | No | No |
| 17591182 | HYDROGEL PRODRUG FOR TREATMENT | February 2022 | March 2023 | Allow | 13 | 1 | 0 | No | No |
| 17579682 | TEAR TRANSPLANTATION AND MULTI-PART CONTACT LENS WITH ABSORBENT PORTION | January 2022 | May 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17572258 | Cardiovascular Prostheses | January 2022 | March 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17572199 | Cardiovascular Prostheses | January 2022 | June 2024 | Abandon | 29 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MERCIER, MELISSA S.
With a 55.6% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MERCIER, MELISSA S works in Art Unit 1615 and has examined 1,215 patent applications in our dataset. With an allowance rate of 70.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner MERCIER, MELISSA S's allowance rate of 70.4% places them in the 25% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MERCIER, MELISSA S receive 2.05 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MERCIER, MELISSA S is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -2.1% benefit to allowance rate for applications examined by MERCIER, MELISSA S. This interview benefit is in the 6% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 24.7% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 53.2% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 75.3% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 58.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 44.7% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.8% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.